Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Õèðóðãèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-õèðóðãîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 04.11.2010, 00:22
Kalachev_AA Kalachev_AA âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 12.10.2010
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 43
Ïîáëàãîäàðèëè 9 ðàç(à) çà 7 ñîîáùåíèé
Kalachev_AA ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
Ëå÷åíèå ãåìàíãèîì

Íà÷àëî çäåñü:
http://forums.rusmedserv.com/showthr...95#post1246895

Èìååò ìåñòî öåëûé ðÿä èññëåäîâàíèé óñïåøíîãî èñïîëüçîâàíèÿ ÷ðåñêîæíîé ëàçåðíîé êîàãóëÿöèè ëàçåðàìè (970 íì, 810 íì), à òàêæå IPL àïïàðàòàìè ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ).
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 04.11.2010, 01:04
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,878
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåêîòîðîå âðåìÿ íàçàä ÿ ñäåëàë äëÿ ñåáÿ íåáîëüøîé îáçîð ïî ïîêàçàâøèìñÿ ìíå íàèáîëåå èíòåðåñíûì ïóáëèêàöèÿì êàñàòåëüíî ëå÷åíèÿ ãåìàíãèîì ñ ïðèìåíåíèåì ëàçåðîâ.  äàííîì ñëó÷àå ÿ èñïîëüçîâàë òîëüêî ïîëíîòåêñòîâûå ñòàòüè (åñëè íóæíî — ìîãó ñêèíóòü). ß íå ïðåòåíäóþ íà ïîëíîöåííûé àíàëèç èìåþùèõñÿ â Ìåäëàéíå äàííûõ ïî ýòîìó âîïðîñó, íî ïðåäñòàâëåíèå î ðîëè ëàçåðîâ â ëå÷åíèè ãåìàíãèîì äåòåé, êàê ìíå êàæåòñÿ, ýòîò îáçîð÷èê äàåò. Êàæåòñÿ, õîòåë åãî â êàêîì-òî ñïîðå èñïîëüçîâàòü, äà òàê è íå ñòàë, à ñåé÷àñ êàæåòñÿ ýòî âïîëíå óìåñòíûì.


Guidelines of care for cutaneous haemangiomas.
Chan YC, Giam YC. Ann Acad Med Singapore. 2005 Jan;34(1):117-23.
Ðàññìàòðèâàåòñÿ ïðèìåíåíèå ëàçåðîâ â òåðàïèè âòîðîé ëèíèè. Ïðåäëàãàåòñÿ ïðèìåíåíèå èìïóëüñíûõ ëàçåðîâ íà êðàñèòåëå ñ ëàìïîâîé íàêà÷êîé (Flashlamp Pulsed Dye Laser — ýòî ëàçåð íà êðàñèòåëå, æåëòûé, íàñêîëüêî ÿ çíàþ).
Öèòàòà:
Due to the limited depth of penetration (about 1.2 mm), this laser is more effective for thin superficial haemangiomas than those with a deep component. It can improve residual telangiectasia after involution and may be effective in treating ulcerated haemangiomas. Multiple treatment sessions at 2- to 4-week intervals are required to achieve significant improvement. In our experience, adverse effects of the pulse-dye laser with an incorporated dynamic cooling device include a bruise-like appearance for up to 2 weeks and dyspigmentation; blistering and scarring are uncommon in skilled hands.

Guidelines of care for hemangiomas of infancy.
American Academy of Dermatology Guidelines/Outcomes Committee. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB. J Am Acad Dermatol. 1997 Oct;37(4):631-7.

 ðàçäåëå õèðóðãè÷åñêîãî ëå÷åíèÿ ãåìàíãèîì «ìàëîãî ðèñêà»
Öèòàòà:
Surgical
1. Flash-lamp pumped pulsed dye laser
2. Other lasers and light sources may be useful in selected cases; however, current lasers other than the flash-lamp pumped pulse dye laser have a greater risk of permanent hypopigmen- tation and scarring. With the exception of the argon laser, information in the medical litera- ture regarding the use of other lasers for treating hemangiomas is sparse.
Hemangiomas: evaluation and treatment.
Dinehart SM, Kincannon J, Geronemus R. Dermatol Surg. 2001 May;27(5):475-85.
Îòëè÷íûé îáçîð îò ñïåöèàëèñòîâ èç: Departments of Dermatology and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, and Laser and Skin Surgery Center of New York.
Êàê âñåãäà, ñòàâêà íà åñòåñòâåííóþ èíôîëþöèþ ãåìàíãèîìû, ëàçåð ïðåäëàãàåòñÿ îïöèîíàëüíî äëÿ ëå÷åíèÿ îñëîæíåííûõ ãåìàíãèîì (ñ èçúÿçâëåíèÿìè), à òàê æå äëÿ ïîâåðõíîñòíûõ è îòíîñèòåëüíî ãëóáîêèõ ãåìàíãèîì â ôàçó ïðîëèôåðàöèè èëè, íàïðîòèâ, â ôàçó èíâîëþöèè. Íî îñîáóþ ëþáîâü, ïîõîæå, àâòîðû èñïûòûâàþò ê óñòðàíåíèþ îñòàòî÷íûõ òåëåàíãèîýêòàçîâ ïîñëå åñòåñòâåííîé èíâîëþöèè ãåìàíãèîìû (ïîêàçàòåëüíûé ïðèìåð ñ ôîòî äåâî÷êè 12 ëåò ñ óñòðàíåíèåì ÒÀÝ ëîáíîé îáëàñòè).

Íåìåöêèé ãàéä ïî äåòñêèì ãåìàíãèîìàì (íàçâàíèå äàíî ïî PubMed).
Hemangiomas in infancy and childhood.
S 2k Guideline of the German Society of Dermatology with the working group Pediatric Dermatology together with the German Society for Pediatric Surgery and the German Society for Pediatric Medicine. Grantzow R, Schmittenbecher P, Cremer H, Hoger P, Rossler J, Hamm H, Hohenleutner U. J Dtsch Dermatol Ges. 2008 Apr;6(4):324-9. Epub 2008 Feb 25.
Öèòàòà:
Laser therapy The use of the flashlamp-pumped pulse dye laser (FPDL) or intense pulsed light (IPL) therapy is indicated for flat lesions.
Òîò æå ëàçåð è òåõíîëîãèÿ èìïóëüñíîé ôîòîòåðàïèè äëÿ ïëîñêèõ ãåìàíãèîì

Hemangiomas of infancy.
Bruckner AL, Frieden IJ. J Am Acad Dermatol. 2003 Apr;48(4):477-93; quiz 494-6. Review.
Òîò æå ëàçåð íà êðàñèòåëÿõ, è òîëüêî äëÿ èçúÿçâëåííûõ ãåìàíãèîì.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 04.11.2010, 01:05
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,878
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñèñòåìàòè÷åñêèé îáçîð ïî ãåìàíãèîìàì
(Pediatr Dermatol. 2008 Mar-Apr;25(2):168-73. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Kilcline C, Frieden IJ.)
âûÿâèë ëèøü îäíî ÐÊÈ ïî ëàçåðó ãåìàíãèîì: Batta K, Goodyear HM, Moss C et al. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet 2002;360:521–527.
×òî ìû âèäèì èç àáñòðàêòà?
Ãåìàíãèîìû ñ ôîðìèðîâàíèåì íà ñðîêå 1 — 14 íåäåëü ïîñëå ðîæäåíèÿ. 60 äåòåé ãðóïïà ëå÷åíèÿ, 61 — êîíòðîëü (áåç ëå÷åíèÿ). Íàáëþäåíèå â òå÷åíèå ãîäà, íå âûáûë íèêòî. ×èñëî äåòåé, ó êîòîðûõ ãåìàíãèîìà ïîëíîñòüþ óøëà, èëè ñîõðàíèëèñü íåçíà÷èòåëüíûå îñòàòî÷íûå ÿâëåíèÿ, íå èìåëî ñòàòèñòè÷åñêèõ îòëè÷èé â îáåèõ ãðóïïàõ. Îäíàêî ÷àñòîòà îñëîæíåíèé — àòðîôèÿ êîæè èëè ãèïåðïèãìåíòàöèè — îêàçàëàñü ñóùåñòâåííî âûøå â ãðóïïå ëå÷åíèÿ. Îöåíêè ðîäèòåëåé ñõîäíû ìåæäó ãðóïïàìè è â ñðàâíåíèè ñ íåçàâèñèìîé ðîäèòåëüñêîé ãðóïïîé.
Öèòàòà:
INTRODUCTION: The role of pulsed dye lasers (PDL) in the treatment of childhood haemangiomas is controversial. Our aim was to compare treatment with PDL with a wait-and-see policy. METHODS: We did a prospective, randomised controlled trial in which we enrolled 121 infants aged 1-14 weeks with early haemangiomas. We assigned infants to PDL treatment (n=60) or observation (n=61), and followed them up to age 1 year. The main outcome measures assessed were proportion of lesions completely clear or with minimum residual signs, adverse reactions, including pigmentary disturbance and skin atrophy, complications such as ulceration and infection, proportion of children whose parents considered the haemangioma a problem, characteristics of the haemangioma, and an independent assessment of the haemangioma problem by a panel of five parents. Analysis was by intention to treat. FINDINGS: All infants completed the study. The number of children whose lesions showed complete clearance or minimum residual signs at 1 year was not significantly different in the PDL treated and observation groups (25, 42%, vs 27, 44%; p=0.92). However, PDL treated infants were more likely to have skin atrophy (17, 28%, vs 5, 8%; p=0.008) and hypopigmentation (27, 45%, vs 9, 15%; p=0.001). The frequency of complications was similar between groups. The only objective measure of resolution that improved with PDL treatment was haemangioma redness. The number of children whose parents considered the haemangioma to be a problem at 1 year did not differ much between groups (11 of 60, 18%, vs 9 of 61, 15%; p=0.78). The independent parent panel validated this result. INTERPRETATION: PDL treatment in uncomplicated haemangiomas is no better than a wait-and-see policy.
Update on hemangiomas and vascular malformations of the head and neck.
Eivazi B, Ardelean M, Baumler W, Berlien HP, Cremer H, Elluru R, Koltai P, Olofsson J, Richter G, Schick B, Werner JA. Eur Arch Otorhinolaryngol. 2009 Feb;266(2):187-97. Epub 2008 Dec 4. Review.
Ðàñøèôðîâàíû îñîáåííîñòè ïðèìåíåíèÿ ëàçåðîâ ðàçëè÷íûõ äëèí âîëí â êëèíè÷åñêîé ïðàêòèêå (ÈÌÕÎ, âåñüìà èíòåðåñíî):
Öèòàòà:
Depending on the size of the vessels, di erent lasers and vessels parameters are predicted and are already used clinically. Small vessels (less than 20m in diameter) are usually spared from destruction in all kinds of laser treatment. This is caused by an insu cient temperature increase inside the vessels due to the small number of light-absorbing red cells (hemoglobin). For vessel diameters ranging from 20 to 200m, visible laser light is applied using frequency-doubled Nd:YAG Laser (532 nm) or FPDL (580–600 nm). The light penetrates the tissue up to 1.5 mm and can coagulate these vessels using pulse durations of 0.5–20 ms. The application of these laser systems yields a reasonable outcome for the treatment of vascular lesion such as PWS, facial teleangiectasia, or hemangioma. Laser light at 400 nm (highest absorption of hemoglobin) is not used in clinical practice, since the penetration of light in this spectral range is limited to less than 0.5 mm. For the treatment of large vessels (0.2–2 mm), near infrared laser light (pulse duration 10–100 ms) is used in clinical practice. Here, the low absorption of infrared light in hemoglobin is compensated by the higher amount of red cells as compared to the small vessels. Because of the large diameter of such vessels and the high absorption coe cient, laser light in the visible spectral range (500–650 nm) would not penetrate the entire vessel leading to incomplete vessel coagulation. Therefore, lasers are used emitting infrared radiation like Nd:YAG laser (1,064 nm) [13]. At this wavelength, light is penetrating the vessel on the one hand, and a Insufficient amount of energy is absorbed by the high number of red cells inside the vessel on the other hand. Consequently, the entire vessel can be destroyed, even in deeper areas of the tissue, since the infrared light is penetrating much deeper as compared to the visible light.
J Am Acad Dermatol. 2008 Feb;58(2):261-85.
Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas.
Stier MF, Glick SA, Hirsch RJ.
Î÷åíü ïîäðîáíûé îáçîð ïî ïðèìåíåíèþ ëàçåðà â ëå÷åíèè âèííûõ ïÿòåí è ãåìàíãèîì ó äåòåé (âêëþ÷àåò è óïîìÿíóòîå ÐÊÈ).
Âûâîä:
Öèòàòà:
Overall, the literature re?ects that laser treatment is safe and effective therapy for PWSs.However, laser treatment of hemangiomas remains controversial, as superficial involuting and ulcerating hemangiomas seem to benefit from laser treatment, but lesions involving deeper components do not.
Dermatol Clin. 2005 Oct;23(4):745-55.
Laser treatment of vascular lesions.
Schmults CD.
Âñå òî æå ñàìîå. Íåò äàííûõ î òîì, ÷òî ëàçåð ìåíÿåò åñòåñòâåííóþ ýâîëþöèþ ãåìàíãèîìû. Ïðèìåíÿåòñÿ ïðè èçúÿçâëåíèÿõ è ò. ï.

Cutis. 2008 Apr;81(4):315-22.
Management of cutaneous hemangiomas in pediatric patients.
Musumeci ML, Schlecht K, Perrotta R, Schwartz RA, Micali G.
Òåðàïèÿ ïåðâîé ëèíèè — ñòåðîèäû:
Öèòàòà:
First-Line Therapy—First-line therapies for CHs include topical, intralesional, and systemic corticosteroids. Topical corticosteroids can be used for low-risk CHs and are efficacious and relativelysafe if used cautiously under medical supervision. The patient should be warned of adverse reactions such as cutaneous atrophy and striae.
Âòîðàÿ ëèíèÿ:
Öèòàòà:
Second-line therapies include interferon alfa-2a and -2b, laser therapy,
and surgical therapy.

It is still unknown, however, if treating uncomplicated CHs with FPDL is more effective than a conservative approach.
Ïðè ýòîì ëàçåðû íà êðàñèòåëÿõ ïðîäîëæàþò ðóëèòü:
Because more complications and greater pain levels are associated with IPL use, FPDL is still the preferred method of treatment for initial superficial CHs.

Èòîã, êàê ÿ åãî ïîíèìàþ:
1. Ëàçåðû ïðèìåíÿþòñÿ äëÿ óñòðàíåíèÿ ïëîñêèõ ãåìàíãèîì, äëÿ ëå÷åíèÿ îñëîæíåííûõ ãåìàíãèîì è äëÿ óñòðàíåíèÿ ðåçèäóàëüíûõ òåëåàíãèîýêòàçîâ.
Äàëåå êàñàòåëüíî íåîñëîæíåííûõ ïîâåðõíîñòíûõ ãåìàíãèîì :
2.  ëþáîì ñëó÷àå îòäàåòñÿ ïðåäïî÷òåíèå âûæèäàòåëüíîé òàêòèêå (åñòåñòâåííîé ýâîëþöèè ãåìàíãèîìû) èëè ïðèìåíåíèþ ñòåðîèäîâ.
3. Íåò äîñòîâåðíûõ äàííûõ, ÷òî â òåðàïåâòè÷åñêèõ ðåæèìàõ ïðèìåíåíèå ëàçåðîâ óñêîðÿåò èíâîëþöèþ ãåìàíãèîì è óëó÷øàåò êîñìåòè÷åñêèé ðåçóëüòàò.
4. Ïðåäïî÷òèòåëüíûìè ñèñòåìàìè íà ñåãîäíÿøíèé äåíü îñòàþòñÿ ëàçåðû íà êðàñèòåëÿõ ñ ëàìïîâîé íàêà÷êîé ñ äëèíîé âîëíû 500 — 600 íì. (ß â Ïèòåðå î òàêèõ íå çíàþ, ïðî Ìîñêâó è Ðàññåþ íå ñêàæó).
Êàê-òî òàê, íàâåðíîå. Òàê ÷òî, áóäåì æå÷ü äåòåé ëàçåðîì?
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 04.11.2010, 01:22
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,878
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Èìååò ìåñòî öåëûé ðÿä èññëåäîâàíèé óñïåøíîãî èñïîëüçîâàíèÿ ÷ðåñêîæíîé ëàçåðíîé êîàãóëÿöèè ëàçåðàìè (970 íì, 810 íì), à òàêæå IPL àïïàðàòàìè ([Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ).
Ïóáëèêàöèé íåìàëî, ýòî òî÷íî. Íî, ê ïðèìåðó, ïðèâåäåííîå Âàìè èññëåäîâàíèå íó íè÷åãî íå ãîâîðèò îá ýôôåêòèâíîñòè èñïîëüçîâàííîãî ëå÷åíèÿ. Èññëåäîâàíèå íåñðàâíèòåëüíîå, íà÷àëè â âîçðàñòå (â ñðåäíåì) 6 ìåñ, 4 -5 ïðîöåäóð ñ èíòåðâàëîì â 4 íåäåëè (òî åñòü, ïî ìåíüøåé ìåðå åùå 4 ìåñÿöà, à îöåíêà ðåçóëüòàòà ïðîâåäåíà ÷åðåç 3 ìåñÿöà ïîñëå ïîñëåäíåãî ñåàíñà. Êàê ìîæíî ðàçëè÷èòü ýôôåêòû îò ëàçåðà è åñòåñòâåííûé ñïîíòàííûé ðåãðåññ ãåìàíãèîì?
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 23:47.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.